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online xxxAnimal models are crucial for improving our understanding of human pathogenesis, enabling researchers
to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive
summary of the most widely used experimental models of chronic liver disease, starting from early
stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and
end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing
the advantages and weaknesses of available models for researchers who are planning to perform animal
studies in the near future. Additionally, we summarise current and prospective models based on human
tissue bioengineering.
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Key point
Animal models represent a
fundamental preclinical
tool to further elucidate the
pathophysiology of chronic
liver disease, and to define
effective treatments and
potential biomarkers.Alcohol-related (AFLD) and non-alcoholic fatty
liver disease (NAFLD) are hepatic insults with
similar pathogenesis and histopathology, ranging
from pure fatty liver and simple steatosis through
alcohol-related (ASH) and non-alcoholic (NASH)
steatohepatitis, to advanced chronic liver disease
(ACLD): stages that encompass fibrosis, progression
to cirrhosis, and end-stage complications such as
primary liver cancer.
Considering the high prevalence of liver disease
worldwide,1 and the lack of preclinical alternatives,
animal models are essential to further elucidate the
pathophysiology of the progression of AFLD/ASH
and NAFLD/NASH to ACLD, and to define effective
treatments and potential biomarkers. In this
comprehensive review we describe the most
widely used experimental models mimicking these
liver diseases, including their pros and cons,
practical advice, and recommendations.
Overall, we show that translating findings from
animals to humans (and vice versa) can be
challenging, but the selection of a valid model that
recapitulates important features of human liver
disease is crucial.
Alcohol-related liver disease
To date, none of the current animal models can
reproduce all major features of human alcohol-
related liver disease (ALD). Rodent models are
often characterised by relatively mild hepatic
damage and an impaired ability to obtain and
maintain a high blood alcohol concentration (BAC),
which can be explained by certain physiological
features: (i) high basal metabolic rate; (ii) natural
aversion to alcohol; (iii) fast catabolism of alcohol;Journa(iv) spontaneous reduction in alcohol intake when
acetaldehyde blood level increases; (v) different
progression time-lines between human (over 10
years of drinking) and rodents (12 weeks of ALD
model); (vi) absence of addictive behaviour and
(vii) differences in the innate immune system.2
Nevertheless, current animal models remain a
very useful tool to study ALD (Fig. 1).
In this section, a summary of the key classical
ALD experimental models is provided (Table 1).
The appropriate selection of a model strongly de-
pends on the scientific question being addressed.
Moreover, it is critical that researchers seriously
consider the impact of several factors, including
rodent strain, age, gender, control groups and
husbandry. All these details should also be clearly
and accurately described in the methodological
section of publications. Most critical factors that
can lead to misinterpretation of phenotypic results
are specified below and outlined in Table 2.
Alcohol in drinking water
Single bottle
Alcohol in drinking water (ADW) is the simplest
model of experimental alcohol administration,
originally developed in the late 70s. In this model,
age and sex-matched animals have free access to a
single drinking bottle containing alcohol in water
and standard rodent chow diet over the course of
several hours, days or weeks. The available
drinking water is supplemented gradually with
increasing amounts of ethanol (normally starting
from 5% (v/v)), and thereafter, the highest
concentration of ethanol is used throughout the
study. Mice drinking alcohol usually consumel of Hepatology 2020 vol. - j 1–18
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Reviewconcentrations up to 25.32% (v/v) and rats as high
as 40% (v/v). Control animals are allowed free
access to rodent chow and drinking water.3 In most
studies, ADW for 8–10 weeks is sufficient to initiate
steatosis. Long-term (months) alcohol feeding has
been reported to induce oxidative stress, steatosis,
very mild fibrosis, increased inflammatory cell
infiltrates, increased hepatic injury, and depletion
of cellular antioxidant defence in mice.4 Rats
maintained on 32.40% w/v ADW for 29 weeks
developed histological changes of fatty liver,
inflammation, focal necrosis and perivenular
fibrosis.5 However, animal care should be consid-
ered when selecting the proposed study length,
since high alcohol content can be associated with
increased mortality.
Multiple bottles
However, the single bottle ADW model is not
suitable for use in non-alcohol-preferring, or low
alcohol-preferring animals, as their aversion to
alcohol will affect their fluid intake. Hence, the
model can be modified to incorporate 2 bottles — a
choice between water and alcohol, or multiple
bottles — a choice between water and alcohol of
varying concentrations. In this variation, individu-
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Journal of Hepatology 2020 vol. - jbottle containing tap water and at the same time to
multiple bottles containing steadily increasing
concentrations of ethanol (3–10% v/v) for a few
days/weeks.5
Because rodents are not forced to drink the
alcohol to assuage hunger or thirst, this method
provides a measure of “spontaneous” consumption,
and the alcohol intake is relatively free of
non-specific effects, such as body size, customary
fluid intake, or minor motor dysfunction.6 More-
over, self-administration of alcohol in this model
appears to share a great similarity with human
addiction, therefore these variations can be used to
explore molecular and neurochemical pathways
that contribute to alcohol abuse in behavioural and
dependence studies.
Moreover, availability is clearly a factor in the
consumption of alcohol in rodents, as is likely the
case in humans. The alcohol intake and preference
of mice and rats is profoundly influenced by the
source of alcohol available. The more bottles of
alcohol the animals have, the more they drink and
thus they will have significantly higher plasma
alcohol concentrations than mice given 1 bottle.6
Yet, it is a challenge to get standard laboratory
rodents to voluntarily consume high amounts of










y of ALD pathogenesis should consider that ethanol is majorly
he oxidation of ethanol is carried out by catalase, a peroxisomal
urther metabolised to acetate by the action of the ALDH. As a
which bidirectionally affect the liver in terms of significant lipid
on, hepatocyte damage, cholestasis and fibrosis. ADH, alcohol
, cytochrome P450 isoenzyme 2E1; ER, endoplasmic reticulum;
NF, tumour necrosis factor; VLDL, very low-density lipoprotein.
1–18
Table 1. Main features of widely used models in alcoholic liver disease (ALD) and NAFLD/NASH.
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++ + + – – BAC [400 mg/dl] Yes121–123 Yes124,125
LdC modifications18 Hepatotoxic substance
(ethanol) + second





























Oral (diet) Rat or
mouse
4–10 weeks +++ +++ ++ In rats129 – Cachexia, no MS Yes130–132 Yes133,134
Choline-deficient
L-amino-defined diet43,45
Deficiency in choline Oral (diet) Rat or
mouse
12–84 weeks +++ ++ ++ Yes, in
CDAA– HFD53
+ Not clear Yes135,136 Yes137,138








– – +MS Yes139,140 Yes49,141
HFD+CD51 Diet rich in
fat + choline deficiency
Oral (diet) Rat or
mouse
24 weeks +++ +++ ++ +53 + +MS Yes142 –
HFD+ fructose57 Diet rich in fat fructose Oral (diet) Mouse 16–30 weeks +++ ++ ++ – – +MS – –
HFD+cholesterol60 Diet rich in
fat +cholesterol










Diet rich in fat
cholesterol
fructose +trans-fats
Oral (diet) Mouse 26–52 weeks +++ ++ ++/+++ – + +MS Yes144 Yes145






12–52 weeks +++ +++ +++ Yes in rat71 Yes in
mouse
Yes70 Yes70,71
APAP, acetaminophen; BAC, blood alcohol concentration; CCl4, carbon tetrachloride; CD, choline deficiency; CDAA, choline-deficient L-amino-defined; DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; HFD, high-fat diet;

























++ General: It induces moderate steatosis and comparatively low elevations of
serum aminotransferases, but no signs of fibrosis or inflammation.
For the DID variation: nutritional effects associated with ethanol con
sumption difficult to assess and control, difficult to sustain considerable
BAC long term, possible dehydration.
Lieber-DeCarli diet + + +++ + + ++ It is not completely physiological since forces ethanol consumption when
animals are hungry or thirsty, requires daily change of the liquid diet during
the experimental period and it does not induce liver inflammation or
hepatic fibrosis even after prolonged administration. Isocaloric diets should
be used if including a paired control group.
LdC modifications: may promote advanced liver disease but are usually
accompanied by lower reproducibility and higher mortality.
NIAAA model ++ + +++ ++ ++ ++ The models still represent only moderate ASH. The combination of long-
term chronic feeding and multiple binges of ethanol feeding is rather
challenging, because of body weight loss and high mortality. In addition,
housing mice in a low-temperature environment and improper technique
during the oral gavage are other leading causes of mortality.
Tsukamoto-French
model
+++ +++ +++ +++ +++ ++ Not a real physiological model, requiring skilled surgical implantation in
combination with expensive equipment. It needs extensive animal
monitoring. Can be classified as severe procedure, thus have potential
difficulties with local ethics committees.
Methionine- and
choline-deficient diet
+ ++ +++ ++ ++ +++ It does not replicate the NAFLD-related metabolic syndrome (decreased
triglycerides and cholesterol, low leptin, absence of insulin resistance,
among others). Animals become cachectic. Scarce transcriptomic similarity
when compared to human NASH
Choline-deficient
L-amino-defined diet
+ ++ +++ + + +++ Very mild gain of weight and unclear increase in hepatic and peripheral
insulin sensitivity.
High-fat diet + ++ +++ + + ++ Requires large sample size due to high inter-individual variability in
steatosis, inflammation and fibrosis.
Differences in species/strains, fat content in diet, duration, etc. difficult
comparison between groups and protocols.
Modified HFD + ++ +++ + + ++ Fructose: no obvious limitations
Cholesterol-modified: Cholesterol content in the diet may not be
physiological
Trans-fats: Prohibition to use trans-fad additives in all type of foods.
Chemical: CCl4-derived metabolites have unknown role in human NASH
pathogenesis
ASH, alcohol-related steatohepatitis; BAC, blood alcohol concentration; CCl4, carbon tetrachloride; DID, drinking in the dark; HFD, high-fat diet; LdC, Lieber-DeCarli; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic












such as sucrose fading, food and water deprivation.
The repeated cycles of excessive drinking and
abstinence, or the so-called intermittent drinking
paradigm, also produces high ethanol consumption
that can be maintained over a longer period.7
Drinking in the dark
The “basic” variation of drinking in the dark (DID)
involves replacing the water bottle with a bottle
containing 20% ethanol for 2 to 4 hours, beginning
3 hours into the dark cycle, in cages of singly
housed mice. Using this procedure, mice typically
consume enough ethanol to achieve psycholog-
ically relevant BAC (>1.0 mg/ml) and exhibit
behavioural evidence of intoxication.8 The DID
model is also quite commonly used to mimic
prenatal human binge drinking.9 The available
variations of this model make it one of the best
suited chronic alcohol abuse models for a wide
range of studies. It is physiological, inexpensive,
without significant mortality and with very simple
animal husbandry. Higher BAC can be achieved if
the ethanol-containing drinking fluid is given
alongside inhibitors of alcohol dehydrogenase that
raise BAC by slowing its metabolism.3,10 Alterna-
tively, flavours can be added to make alcohol taste
better.
ADW + second hit
As mentioned, despite the widespread use of the
ADW model, there are important limitations in the
severity of ALD progression (Table 2). Therefore,
modified experimental models using secondary
hepatic stressors have been widely used. For
example, diethylnitrosamine (DEN) and alcohol act
synergistically to induce liver injury, further
promoting hepatocellular carcinoma (HCC) devel-
opment and suitably mimicking human ALD.11 A
single dose of DEN given at a late stage on an
8-week, 10/20% (v/v) ADW (alternate days) regime
significantly increased tumour incidence and
burden, but only in male mice.12
Likewise, several approaches have been pursued
to combine carbon tetrachloride (CCl4) applications
with alcohol. In a recent study,13 advanced liver
injury was achieved by supplementing CCl4
exposure with ADW. Yet, the use of hepatotoxic
chemicals, including CCl4 or DEN, to study fibrosis
is likely to represent the effects of the toxin more
than ALD. Therefore, more physiological models
that mimic the typical drinking pattern are
urgently required.
BASH (both alcohol-related and
non-alcoholic steatohepatitis)
In the prosperous parts of the world, lifestyles
often include the overlapping of alcohol intake
with high fat consumption. Consistently, moderate
alcohol consumption was related to an increased
risk of NAFLD progression, leading to advancedJournafibrosis14 and hampering disease resolution.15
Some animal models have already been suggested
to evaluate the influence of dietary factors on
chronic alcohol-induced liver injury.16 As an
example, a combination of ADW (5%) with high-fat
diet (HFD) for 6 weeks leads to enhanced
expression of proinflammatory genes, activation of
hepatic stellate cells (HSCs), and extracellular
matrix (ECM) deposition in the liver tissue, with
synergistic effects on fibrosis development.16 A
complementary model that combines HFD feeding
followed by gavage with a single dose of ethanol
induces liver inflammation and injury through the
elevation of hepatic and serum free fatty acids,
leading to hepatic neutrophil infiltration.17 This
model could be used to study the effect of
interactions between obesity and binge drinking
on liver inflammation and injury.17 Still the new
BASH models from other laboratories are awaited
with interest as a major advance in this field.
The Lieber-DeCarli diet
Although the ADWmodel was widely used for mild
alcoholic liver injury, the need for a method which
achieves significant BAC and allows reasonable and
controlled nutrition led to the development of a
unique liquid diet procedure over 25 years ago by
Charles Lieber in collaboration with his technical
assistant Leonore M. DeCarli.3,10,18
In order to overcome the aversive gustatory
properties of alcohol, the Lieber-deCarli (LdC) diet
involves incorporating ethanol into a liquid only
diet. When rodents have nothing to eat or drink
except the ethanol-containing liquid diet formula,
their intake is sufficient to sustain a high ethanol
consumption of 14 to 16 g/kg/day, which approxi-
mately resembles the intake of 3.4 L of whiskey
(40% v/v) in a 75 kg human.18 The amount of
ethanol in the diet should be increased gradually,
up to the final concentration of 6.4% v/v, during a
primer period of approximately 5 days. This allows
the animal to adapt to the ethanol-containing diet
gradually, thus ensuring the effect of subsequent
formal feeding. The diet is also supplemented with
essential fat-soluble vitamins (A, D, E, K) and
water-soluble vitamin B12, minerals and fibre.3
Depending on the scientific question or the
rodent's species, strain and gender the duration of
the LdC feeding can be modified. The earliest step
of ALD may manifest as early as 3 to 4 weeks after
alcohol exposure. Four weeks of LdC represents an
excellent model to study the initial stages of ALD
with mild steatosis, slightly elevated aminotrans-
ferases, and minor inflammation.19,20 Stepwise
feeding with the LdC up to 8 to 12 weeks induces
remarkable fatty liver with mild inflammation and
moderate liver damage, without fibrosis.21 For the
development of the advanced form of ALD, second
hit models are recommended instead of prolonging
the diet.l of Hepatology 2020 vol. - j 1–18 5
Key point
Mostly due to animal's
aversion to alcohol, current
preclinical models
mimicking alcoholic liver
disease do not reproduce
all major features of human
disease; however, they are
useful to understand key
pathophysiological events




One of the most well-known modifications of the
LdC diet is the NIAAA model developed by the
group of Bin Gao.22 According to the protocol, mice
receive LdC containing 5% v/v ethanol for 10 days. A
single dose of ethanol (5 g/kg body weight) is given
at day 11, and 9 hours later animals are euthanized.
This model can be extended to longer periods of
chronic feeding (up to 8 weeks) and combined
with multiple binges.
This protocol triggers higher BAC, more severe
steatosis, hepatocellular damage, and hepatic
neutrophil infiltration, compared with LdC feeding.
However, it still represents only early ASH. Long-
term chronic feeding and multiple binges of
ethanol feeding induce more severe steatohepati-
tis; however, it is challenging to establish due to
body weight loss and high mortality. The model
mimics alcoholic liver injury in the form of heavy
binge drinking in chronic alcohol abusers.23
Other LdC variations
Besides binge drinking, other hepatotoxins
including DEN,24 CCl4,25,26 lipopolysaccharide
(LPS)27,28 or acetaminophen (APAP)29 can be added
during chronic LdC feeding to provide a “second
hit” and increase liver damage. These studies have
expanded the use of the LdC diet and provide
useful insight into the effects of ethanol on the
progression of severe liver injuries such as cirrhosis
or HCC.
For example, the severity of fibrosis is signifi-
cantly magnified by combining alcohol and CCl4 in
a dose-related manner.25 The group of Laura Nagy
established an interesting model where mice are
subjected to chronic CCl4-treatment combined
with the LdC diet containing moderate concentra-
tions of ethanol (2% v/v), leading to hepatocyte
apoptosis, HSC activation and accumulation of
ECM.30
Another synergistic model which may deserve
attention is the combination of LPS with the LdC
diet, which mimics leakage of bacterial products
such as LPS from the intestine into the blood,
leading to the release of various proinflammatory
cytokines that ultimately exacerbate steatohepati-
tis, liver injury and fibrosis.27,28
Finally, we obtained a new model of advanced
ALD by administering the LdC diet to transgenic
mice overexpressing the c-MYC oncogene specif-
ically in hepatocytes; these mice exhibited early
ballooning degeneration, incremental collagen
deposition and altered fat metabolism. Long-term
feeding resulted in substantial fibrosis and
expression of pre-neoplastic markers.19,31
The Tsukamoto-French model
To overcome the limitations of the LdC diet and
reach the advanced stages of ALD, in 1984 Tsuka-
moto and co-workers developed a new feeding
model of direct ethanol infusion through aJournal of Hepatology 2020 vol. - jsurgically implanted intragastric cannula. In this
model, a catheter is implanted into the stomach
under aseptic conditions. Alcohol is added to the
LdC diet and infused via the implanted catheter
directly into the stomach with the aid of an
infusion pump.32,33
This model is really valuable because the
investigator has complete control of ethanol intake
and diet, as well as administration rate (amount)
and mode of delivery (continuous, intermittent or
bolus). Moreover, the dietary factors can be
manipulated and a second hit such as LPS admin-
istered enterally.34 The animals can be maintained
on the diet for several months, and blood alcohol
levels of 250–500 mg/dl can be achieved and
sustained. The application of this model leads to
pathologic changes which resemble human ALD,
including microvesicular and macrovesicular fat,
megamitochondria, apoptosis, central necrosis, and
mixed inflammatory infiltrate including poly-
morphonuclear cells and lymphocytes, central
lobular and pericellular fibrosis, portal fibrosis,
bridging fibrosis, but not cirrhosis or other
irreversible changes.3,35 Another interesting
modification is the “hybrid” combination of the
Tsukamoto-French model with ad libitum feeding
of a western diet (WD).36
Non-alcoholic fatty liver disease
Animal models that mirror the pathophysiology of
every stage of human NAFLD progression provide
important insights into disease pathogenesis,
guiding the development of much needed thera-
peutic options (Fig. 2). This section summarises the
current and most frequently used animal models in
NAFLD research, focusing on each model's major
advantages and drawbacks (see also Tables 1 and
2). NAFLD researchers must have a very clear un-
derstanding of which pathological event they aim
to study in order to choose the animal model that
best suits their research goals.
Methionine- and choline-deficient diet
The methionine- and choline-deficient (MCD) diet
has been widely used in NAFLD animal studies.
MCD is high in sucrose (40%) and provides a
moderate amount of fat (10%) but is deficient in
methionine and choline. Methionine is an essential
amino acid that cannot be synthesized de novo and
is a crucial compound for the synthesis of cysteine,
lecithin, phosphatidylcholine and many other
macromolecules. Similarly, choline is a constituent
of cell and mitochondrial membranes and a
precursor for acetylcholine, a well-known neuro-
transmitter.37,38 Due to the deficiency of both
components, the synthesis of phosphatidylcholine
is impaired, resulting in diminished VLDL assembly
and secretion. Consequently, triglyceride (TG)
clearance is reduced and lipids accumulate in the
liver. Other pathological features of this model
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Fig. 2. Towards an ideal experimental model of NAFLD/NASH. The ideal characteristics of an animal model of NAFLD/NASH should mimic human disease with
respect to its development by diet-induced obesity and insulin resistance (the most common risk factors for the disease in humans), thus triggering predom-
inantly macrovesicular steatosis, lobular inflammation, hepatocellular ballooning and/or with Mallory-Denk bodies and, activation of hepatic stellate cells and
consequently liver fibrogenesis. An important model of NAFLD should not only recapitulate the diet, systemic milieu and histological spectrum of the disease but
also demonstrate activation of key cellular pathways, such as ER stress, lipotoxicity and activation of de novo lipogenesis. In addition, other pathogenic elements
such as oxidative stress, apoptosis and fibrogenic pathways that are relevant in human disease should also be activated. Advanced fibrosis is required when
studying NASH. Moreover, it has also become clear that intestinal dysbiosis plays a pivotal role in disease progression. CCL2, C-C motif chemokine ligand 2; ER,
endoplasmic reticulum; FFAs, free fatty acids; IL-6, interleukin 6; LPS, lipopolysaccharide; ROS, reactive oxygen species; TNF, tumour necrosis factor.induction of CYP2E1-derived oxidative stress,
and depletion of hepatic anti-oxidants, promoting
reactive oxygen species (ROS) and steato-
hepatitis.39
The MCD model replicates part of the histolog-
ical phenotype typical of human NASH in a
relatively short period. It usually takes 3 weeks to
develop obvious steatohepatitis and 5–8 weeks for
appreciable fibrosis.40 After 10 weeks of MCD
feeding, a large number of necroinflammatory foci
containing lymphocytes and neutrophils can be
observed in the murine liver tissue,41 associated
with markedly elevated plasma alanine amino-
transferase levels.
However, it does not replicate the NAFLD-
related metabolic syndrome. Mice fed the MCD
are cachectic and by 8 weeks of feeding lose 40% of
their weight, most likely because of a hypermeta-
bolic state.40 Moreover, animals have decreased
plasma TG and cholesterol levels and reduced liver
weight/body weight ratio. Additionally low serum
levels of leptin, unchanged or increased adipo-
nectin, an absence of overt insulin resistance, with
low fasting blood sugar and peripheral insulin
sensitivity, create a metabolic profile opposite toJournathe human disease.42 Importantly, there is also a
poor concordance between differentially expressed
genes in this model and human NASH.7 Thus, the
use of the MCD model is limited by the disparity in
metabolic changes observed between the model
and the vast majority of human patients with
NAFLD.
Choline-deficient L-amino-defined diet
Like the MCD diet, the choline-deficient L-amino-
defined (CDAA) diet is also deficient in choline. In
contrast, the semisynthetic CDAA diet has normal
or only moderately lowered levels of methionine
and the proteins in the formula are comparably
replaced by a mixture of L-amino acids.43 Hence,
the development of experimental NAFLD takes
longer with the CDAA than the MCD diet. Steato-
hepatitis occurs after 12 weeks of the CDAA diet
and is accompanied by mild ballooning and
fibrosis, with an approximately 3-fold increase in
hepatic collagen levels. Fibrosis further progresses
to moderate stages after approximately 21 weeks
of feeding. Moreover, CDAA-fed rodents frequently
exhibit hepatic tumours associated with fibrosis;
thus, they can be used to study the progressionl of Hepatology 2020 vol. - j 1–18 7
Key point
Animal models for NAFLD/
NASH are diverse, mostly
based on nutritional inter-
vention, and their patho-
physiology ranges from
simple steatosis to
advanced liver fibrosis. The
latter is obtained when
combining nutritional
intervention with a second
proinflammatory hit.
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Reviewfrom NAFLD to NASH and further to HCC.40,44
Interestingly, female mice did not develop these
lesions.45
High-fat diet
Aimed at recapitulating the pathogenesis of human
NAFLD, obesogenic or the so-called HFDs are
widely used to generate obesity and NAFLD in
rodents. These diets are particularly rich in fat
without any artificial nutrient deficiencies. In the
first paper from the 1940s, Samuels et al.46
reported that rats fed with a diet containing 70%
energy as fat developed obesity and elevated basal
and postprandial blood sugar values. From subse-
quent studies, it is now accepted that HFD (ac-
counting for 45–75% of total calorie intake from
fat) may be used to generate metabolic syndrome,
hepatic steatosis and NASH in experimental
animals.
Furthermore, the severity of HFD-induced
NAFLD may depend on the: i) species — rats
appear to be more sensitive than mice and require
a shorter time for severe histological NAFLD
manifestation47; ii) gender — male mice are more
susceptible than females, as oestrogen (the major
female sex hormone) is protective against
NAFLD48; iii) strain of the animals, (e.g. Sprague-
Dawley rats fed with HFD easily develop
steatohepatitis, while Wistar rats are resistant41).
In mice, the C57BL/6 strain exhibits high sensitivity
to HFD. In contrast, BALB/c and C3H/HeN are
significantly less prone to develop diet-induced
hepatic necroinflammation.44 In fact, irrespective
of diet, C57BL/6 mice are already genetically prone
to obesity, hyperinsulinemia and glucose intoler-
ance as they age.
The importance of the genetic background has
been exemplified in the diet-induced animal model
of NAFLD.49 Sanyal's group developed a novel
inbred isogenic mouse strain, derived from the
C57BL/6J and 129S1/SvImJ backgrounds, that upon
feeding with 0.1% cholesterol HFD + fructose/
sucrose-enriched drinking water results in
obesity, insulin resistance and a time-dependent
progression of NAFLD. Bridging fibrosis and HCC
were observed in almost all mice at week 52. These
mice recapitulate the key physiological, metabolic,
histologic, transcriptomic and cell-signalling
changes seen in humans with progressive NAFLD.
However, a major drawback of the model relates to
the fact that most knockout or transgenic animals
are typically maintained on more commonly
available backgrounds (such as C57BL/6 and B6/
129), thus this model is not readily available for
such studies.44,50
Apart from this, HFD-fed animal models present
other limitations highlighted in Table 2. Therefore,
they should mainly be used for the characterisation
of potential drug effects on body weight, hepatic
steatosis, and, to some extent, inflammation.Journal of Hepatology 2020 vol. - jModified HFD
CD diets
Among various dietary approaches, the interesting
combination of HFD with choline deficiency (CD-
HFD) reported by the group of Heikenwalder51 and
others52,53 deserves closer attention. Indeed, long-
term application of CD-HFD fully recapitulates
chronic metabolic disorders leading to advanced
NAFLD. In addition to severe steatosis, the livers of
CD-HFD mice displayed all features reminiscent of
human NASH including ballooned hepatocytes,
infiltration of immune cells, satellitosis, Mallory-
Denk bodies and glycogenated nuclei. Moreover,
CD-HFD feeding induces oxidative stress and
mitochondrial damage and causes mild pericellular
fibrosis accompanied by activation of HSCs. At 24
weeks, mice developed signs of cirrhosis with
severe perisinusoidal pan-lobular chicken wire
fibrosis, regenerative nodule formation, pro-
nounced ductular reaction and significant portal
hypertension.53 Importantly, within 24 weeks all
CD-HFD-fed animals develop tumours, fully
resembling human HCC.51,53
In order to amplify NAFLD and trigger a robust
fibrotic response without significantly compro-
mising nutrient balance, different modified HFDs
with increased levels of fructose and/or cholesterol
have been used.44
Fructose
Recent studies suggest that over-consumption of
fructose, primarily in the form of soft-drinks, is
tightly linked to weight gain and increases the risk
of NAFLD, particularly in children and adoles-
cents.54 In animals, as well as in clinical studies,
fructose stimulates de novo lipogenesis and blocks
hepatic b-fatty acid oxidation leading to fat accu-
mulation in the liver.55 In addition to these direct
effects, fructose contributes to intestinal dysbiosis,
impaired intestinal barrier function and increased
translocation of bacterial metabolites in NAFLD.56
Experimental animals fed a fructose-enriched
diet are recognised as good models of metabolic
syndrome. High fructose feeding for a long duration
(up to 30 weeks) typically results in steatohepatitis
progressing to moderate fibrosis. In the experi-
mental study from Kohli et al.,57 C57BL/6 mice were
fed ad libitum with a high-fat high-carbohydrate
diet (58% of calories from fat) and drinking water
with high fructose (55% fructose) over a 16-week
period; these mice developed a phenotype
encompassing obesity, insulin resistance, hepatic
injury, oxidative stress, macrophage infiltration, and
fibrosing NASH.41,48 Similarly, hepatocellular injury,
inflammation, and hepatic fibrosis were reported in
the rats fed with a fructose-enriched diet.41,57,58
Cholesterol
Many epidemiological studies have identified dietary
cholesterol intake as a factor related to the risk and1–18
severityofNAFLD.59 In linewith this concept, the liver
phenotype of HFD-based mouse models can be
aggravated by increasing cholesterol concentrations
in the diet. Thus, C57BL/6 mice fed with cholesterol-
containing HFD for 16–20 weeks develop more pro-
nounced liver damage, inflammation and fibrosis
than animals fed with HFD without cholesterol.
Cholesterol significantly increased serum leptin,
interleukin-6, liver weight and insulin resistance,
thus leading to a phenotype that closely resembles
the clinical features of NASH in patients with meta-
bolic syndrome.60 It is important to note that 2%
cholesterol diets (frequently used) are not physio-
logical, and those dietswith lower cholesterol (which
more closelymodel human cholesterol consumption)
may either not induce NAFLD or do so in a time frame
that is economically (in time and money) unrealistic.
In practice, to induce NASH and significant liver
fibrosis within reasonable time frames (usually
around 4 to 6 months) an increasing number of
studies are using HFD enriched with both fructose
and cholesterol. Such diets are referred to as “fast
food diet” or “western diet (WD)”. In humans, a
“western” dietary pattern is characterised by high
intakes of red/processed meat, fast food, refined
grains/cereals, sugar-sweetened beverages, eggs,
sweets/desserts and low intake of fruit and vegeta-
bles or dairy products. This diet induces obesity,
metabolic syndrome and NAFLD. Nowadays, com-
mercial diet companies sell many open-source for-
mulations of WD for animal research. However,
researchersmust be cautious, because animalWDdo
not fully recapitulate many features of this human
dietary pattern (e.g., diverse fat sources, amounts of
micronutrients). For example, the micronutrient
content of these WD is formulated to promote ani-
mal health, which is totally inconsistent with the
western dietary pattern in humans.61 Therefore,
these diets should be considered as powerful tools to
generate disease, such asNAFLD for example, but not
as a model of “western” nutrition.
Amongst other studies, an excellent WD model
has been introduced by Charlton and colleagues.62
In this study C57BL/6 mice were fed with HFD (40%
of energy as fat, milk fat, 12% saturated) enriched
with 0.2% cholesterol. Additionally, high-fructose
corn syrup was also administered in the drinking
water. By 6 months, animals exhibited all the
hallmarks of advanced NAFLD most commonly
observed in humans, including obesity, metabolic
syndrome and steatohepatitis. Importantly, the
most significant new feature of this model was the
presence of hepatocellular ballooning and pro-
gressive fibrosis.
Trans-fats
Addition of dietary trans-fats has been reported to
enhance the steatogenic and pro-fibrotic properties
of WD in mice.44 The underlying molecular
mechanisms are not fully understood, but trans-
fats likely sensitise mice to the effects of HFD byJournaincreasing insulin resistance, hepatic lipogenesis
and oxidative stress.63
Consequently, an ‘American Lifestyle-Induced
Obesity Syndrome’ (ALIOS) mouse model of NASH
was developed by Tetri and colleagues64 and subse-
quently refined by other laboratories.65,66 In both
variations of the diet, the source of the trans-fats is
partially hydrogenated vegetable oil. However, the
cholesterol content in themodifieddiet is greater, and
fructose was provided in the food pellets rather than
in the drinking water. C57BL/6 mice treated with
these diets develop obesity, hepatic insulin resis-
tance, hyperinsulinemia, marked steatosis, moderate
lobular inflammation, and mild-stage hepatocellular
ballooning within 26–30 weeks of dieting, and HCC
after 52 weeks.67 In general, the model accurately
reflects patterns associated with human NAFLD and
replicates features of metabolic syndrome, therefore
representing an excellent preclinical model for iden-
tifying pharmacological interventions with greater
likelihoodof being translated into the clinic.However,
the FDA has recently imposed a ban on the use of
trans-fat additives in all type of foods including ani-
mal diets. This prompted the development of non-
trans-fat WDs, with similar nutrient composition,
capable of promoting comparablemetabolic and liver
histopathological changes.68
Chemical
Based on ‘multiple-hit’ theory for the development
and progression of human NALFD, few animal
models successfully combined obesogenic diets
with CCl4 administration.
69–71 In this setting, CCl4
potentiates the effects of an HFD towards the fast
development of NASH and fibrosis.
Kubota et al.were among the first to show that a
combined model of HFD feeding and CCl4 admin-
istration induced hepatic steatosis, inflammatory
cell accumulation, hepatocellular ballooning,
fibrosis, and increased serum aminotransferase
levels after 12 weeks.69 Two subsequent studies
performed in mice and rats recapitulated those
findings,70,71 and showed that a combination of
HFD with CCl4 leads to prominent F4 fibrosis (i.e.,
cirrhosis after 24 weeks of protocol). Interestingly,
in both studies, rodents subjected to these novel
protocols developed progressive NASH-like histol-
ogy despite the fact that adding CCl4 treatment to
HFD feeding attenuated typical HFD-induced in-
creases in body weight, cholesterol and insulin/
glucose levels. Last, but not least, global tran-
scriptome profiling of the liver by RNA sequencing
showed that the dysregulated molecular pathways
in WD/CCl4 rodents at 12/24 weeks were compa-
rable to those of mild/advanced human NASH.Animal models of advanced chronic liver
disease
Albeit the causes of chronic liver disease (CLD) may
vary, the progression of the disease converges inl of Hepatology 2020 vol. - j 1–18 9
Liver
Advanced fibrosis and portal hypertension:
•   Formation of regeneration nodules
     surrounded by fibrous septa
•   Vascular occlusion
•   Parenchymal extinction
•   Hepatic microcirculatory dysfunction
•   Formation of porto-systemic collaterals
Liver sinusoidal endothelial cells
•   Loss of fenestrae and development of a basal
     membrane
•   Acquisition of a vasoconstrictor, pro-
     inflammatory and pro-thrombotic phenotype
Kupffer cells
•   Synthesis of pro-inflammatory cytokines,
      chemokines, reactive oxygen and nitrogen species
•   Secretion of vasoconstrictor molecules
Brain
Hepatic encephalopathy:
•   Hyperammonemia
•   Impairment of neurotransmission
•   Neuroinflammation
•   Brain oedema
Kidney
Hepatorenal syndrome:
•   Overproduction of creatinine
•   Vasoconstriction
•   Decrease of glomerular filtration rate
Gut
Intestinal barrier dysfunction:
•   Loss of barrier integrity
•   Bile acid dysregulation
•   Increased inflammatory mediators
•   Dysbiosis
Hepatocytes
•   Necroapoptosis
•   Release of DAMPs
•   Impaired protein synthesis and
     detoxification capacity
Hepatic stellate cells
•   Transdifferentiation to myofibroblasts-like cells
•   Loss of vitamin-A lipid droplets
•   Exacerbated synthesis and deposition of
     extracellular matrix
•   Hypercontractility
•   Increased migration and proliferation
Spleen
•   Splenomegaly and hypersplenism
Fig. 3. Main alterations present in animal models of advanced chronic liver disease. An animal model of ACLD that closely mimics the pathophysiology of the
human disease should exhibit a profound deregulation both at the systemic and cellular levels. In the liver, all cell types are affected, including hepatocyte
necroptosis, hepatic stellate cell activation, liver sinusoidal endothelial cell capillarisation, and Kupffer cell shift to a proinflammatory phenotype. Altogether,
these alterations cause histological distortion and vascular occlusion in the liver, leading to the development of portal hypertension, one of the most relevant
syndromes associated with ACLD. At advanced stages, portal hypertension can cause severe systemic complications, such as hepatic encephalopathy, intestinal
barrier dysfunction or hepatorenal syndrome, among others. ACLD, advanced chronic liver disease; DAMPs, damage-associated molecular patterns.
Key point
Animal models of cirrhosis
derive from chronic expo-







chronic liver failure (ACLF)
are also described.
10
Reviewcirrhosis and may even progress, in some cases, to
HCC. Cirrhosis, or ACLD, is characterised by an
excessive deposition of ECM in the liver, leading to
the formation of regenerative nodules surrounded
by fibrous bands, parenchymal extinction, and
vascular occlusion. One of the most relevant syn-
dromes associated with ACLD is portal hyperten-
sion, which has serious clinical complications.72
Even though research efforts to find an effective
treatment for ACLD have dramatically increased in
recent decades, liver transplantation currently re-
mains the only therapeutic option. While some
promising candidates are emerging,73 there is still
a long path of preclinical research to undergo
before they reach the bedside. For this reason, it is
essential to have well-characterised animal models
that closely mirror the specific aspects of ACLD
(Fig. 3).
Preclinical models of ACLD that are based on the
administration of hepatotoxic substances are the
most widely used by researchers worldwide.
However, other types of model exists (such as
surgical models), as well as models of specific ae-
tiologies of cirrhosis. We will summarise herein the
most relevant and widely used animal models forJournal of Hepatology 2020 vol. - jACLD research, as well as their main drawbacks
and advantages. However, a more extensive list of
models can be found in Table 3.
Carbon tetrachloride
CCl4 is metabolised in the liver by cytochrome P450
enzymes and converted to a highly reactive tri-
chloromethyl (CCl3C) radical, ultimately leading to
hepatotoxic damage, inflammation and fibrosis.74
Although it can also be used in shorter protocols
for the study of acute liver injury, chronic admin-
istration of CCl4 has long been one of the most
widely accepted models of ACLD. However, a great
variety of protocols exist, making it sometimes
difficult to compare results from different research
groups. In general, CCl4 is administered to rats or
mice through intraperitoneal injection or inhala-
tion. Alternatively, it can be delivered by oral
gavage, although there have been mixed reports
regarding mortality rates using this route.75,76
Intraperitoneal injection
CCl4 is dissolved in mineral or vegetable oil and
intraperitoneally injected into rats or mice





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of its vapours, CCl4 should be handled inside a
fume hood. The dose must be adjusted by animal
body weight, and typically ranges between 0.5–2.0
ml/kg.77,78 The duration of the protocol may vary
depending on the dose and species chosen but is
generally 6–12 weeks. It is important to note,
however, that most intraperitoneal mice models
described only reach a stage of CLD that could be
defined as fibrosis or early cirrhosis.
Inhalation
CCl4 can equally be administered through inhala-
tion. This model has traditionally been used in rats
for the study of portal hypertension and its com-
plications,77,79,80 and it has more recently been
adapted for use in mice.78 In both cases, the ani-
mals must be placed in a closed chamber, inside a
fume hood, connected to a source of compressed
oxygen bubbling through a CCl4 flask at a usual rate
of 1 L/min. In most protocols, animals are subjected
to this CCl4 atmosphere 2/3 times per week,
increasing the exposure time every week.77 More-
over, phenobarbital can be added to drinking water
(0.3 g/L) to shorten the required time to reach
cirrhosis, as McLean et al. first described in 1969.81
After 13–16 weeks, animals will develop ascites,
marking the development of decompensated
cirrhosis.
In general, CCl4-induced ACLD constitutes a
reliable model of the human pathology, mimicking
all its crucial aspects both at the physiological and
cellular level. CCl4-cirrhotic animals present a
profound deregulation of all the cell types present
in the liver, including hepatocyte necroapoptosis,
HSC activation, liver sinusoidal endothelial cell
capillarisation and macrophage recruitment. It is of
particular interest for the study of decompensated
stages of cirrhosis since CCl4-cirrhotic animals
often present ascites, among other signs of
decompensation. Nonetheless, some technical as-
pects must be considered when using this model
(Table 4). Firstly, a suitable strain must be selected,
as not all strains of mice or rats are equally sus-
ceptible to the damage produced by CCl4. BALB/c
have been described to be the most adequate
among mice82 while, in our experience, Wistar rats
present higher CCl4-susceptibility. Even among
animals of the same strain, there can be a certain
heterogeneity in the degree of cirrhosis obtained,
which is characteristic of this model. In rats, intra-
animal heterogeneity can be diminished by
selecting animals for study once they have devel-
oped ascites, an unequivocal sign of cirrhosis
decompensation, rather than selecting them based
on the weeks of toxicant administration. None-
theless, the number of animals per experimental
group must be sufficient to compensate for said
variability. Regarding sex-related differences, it has
been reported that female Sprague-Dawley rats
respond more severely to acute CCl4 than males,
while also presenting a greater extent of tissueTa E m C T c
B D D D M A AC ni
t
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CCl4 + +++ + (inhaled)
++ (i.p.)
+ + ++ Differences in administration route, frequency, and dose are
associated with discrepancies between studies and research teams.
For CCl4 inhalation, special facilities and equipment are required.
Animal tolerability to CCl4 varies, making it difficult to have homogeneous
groups. Necessity to increase the n.
CCl4 withdrawal may lead to partial fibrosis regression.
TAA + +++ ++ + + ++ Possible low yield of cirrhosis when TAA is administered in drinking water.
High variability in fibrosis grade.
Significant mortality if TAA dose is not corrected to body weight.
cBDL ++ + +++ ++ ++ +++ Not adequate for studies involving pharmacological drugs eliminated
through the biliary route.
Extrinsic compression of portal vascular structures due to exaggerated
dilatation of the remnant extrahepatic bile duct.
cBDL, common bile duct ligation; CCl4, carbon tetrachloride; TAA, thioacetamide; +, low; ++, moderate; +++, high.
Key point
All animal models present
pros and cons, which are
herein summarised. Stand-
ardisation of protocols, as
described in this review, is
key to obtain reproducible
and representative results,
and therefore a higher
impact in the field.
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Reviewrepair and cellular regeneration.83 Lastly, CCl4-
induced ACLD exhibits a relatively rapid rate of
partial regression once the toxicant is removed,
therefore being of specific interest for the study of
fibrosis regression.84
Thioacetamide
After CCl4, thioacetamide (TAA) is the second most
widely used model of hepatotoxin-induced ACLD.
Its hepatotoxicity, first reported in rats in 1948,85
stems from the generation of highly reactive me-
tabolites in the liver that can bind to proteins and
lipids causing oxidative stress and necrosis.86 In the
past decades, TAA has been extensively used both
in mice and rats; it is generally administered by
intraperitoneal injection or in drinking water.
Intraperitoneal injection
For its intraperitoneal delivery, TAA is dissolved in
saline solution and the dosage is adjusted by body
weight. There are a variety of published protocols
of TAA-induced cirrhosis with differences in dose
and frequency of administration. In our experience,
Sprague-Dawley rats receiving TAA twice per week
at a dose of 250 mg/kg will develop ACLD in 12
weeks.87 Others have described milder guidelines
for its use in mice (200 mg/kg twice per week for
8–10 weeks),88 but many of them only reach
fibrosis or an early stage of cirrhosis. Moreover,
abdominal adhesions should be expected.
TAA in drinking water
Alternatively, TAA can be added to drinking water
at a concentration of 300 mg/ml, for a duration of
12 weeks.89 Some research groups have reported
alternative protocols in which TAA concentration
was gradually increased according to body weight
gain throughout the duration of ACLD
induction.89,90
Overall, TAA constitutes a highly reliable and
reproducible model that effectively mirrors the
patterns of human ACLD.91,92 It presents a low
mortality rate when dosage is correctly adjusted byJournal of Hepatology 2020 vol. - jbody weight and requires little technical training
and equipment. Moreover, the fibrosis developed
with this model persists for weeks after TAA
withdrawal and is more similar in nature to human
fibrosis compared to other toxicants such as CCl4,
presenting more prominent regenerative nodules
and a periportal and lobular distribution.2 Also,
unlike CCl4, where genetic background plays a key
role in toxicant-susceptibility, no strain-related
variability has been reported for TAA. However, a
certain inter-individual variability in the degree of
fibrosis reached is to be expected.
Common bile duct ligation
Common bile duct ligation (cBDL) is a model of
secondary biliary cirrhosis that can be performed
both in rats and mice. The surgical obstruction of
the common bile duct causes bile to accumulate in
the liver, leading to hepatic injury, inflammation
and, ultimately, fibrosis and cirrhosis.93,94
Briefly, the animal is anesthetised and placed in
a disinfected surgical area. After an abdominal
incision along the linea alba, the common bile duct
is isolated. A double ligature is performed, with the
distal ligature being at the cross section of the
duodenum and the common bile duct, and the
proximal ligature being as close to the junction of
the hepatic ducts as possible. Finally, the bile duct
is resected between the 2 ligatures and both
abdominal layers, the peritoneum and abdominal
skin, are closed separately with simple interrupted
sutures. After 3–4 weeks, both mice and rats will
exhibit ACLD.95,96 To increase survival, it is rec-
ommended to administer vitamin K once per week
until the end of the protocol.97 Additionally, anti-
biotics can be administered during the first few
days after surgery. However, they may not be
necessary if surgery was performed under sterile
conditions and they could interfere with some as-
pects of the disease, such as bacterial translocation.
While it requires a certain degree of surgical
expertise, especially when performed in mice, cBDL
constitutes a relatively simple and highly1–18
Table 5. Overview of current and future methods in hepatic tissue bioengineering.
Liver model System Disease Culture Advantages Weaknesses
Spheroids182 In vitro NAFLD/NASH PHH, IC, NPC High-throughput drug screening,
co-cultures with NPC possible
without any specialised system
Cell choice can modify the output,
suboptimal cell–cell interaction,
access to fresh human tissue,
healthy tissue not really extracted
from healthy individuals, lack of
complete hepatocyte polarity
Organoids108 In vitro NAFLD/NASH,
HCC/CCA
PSC A genetically stable 3D model,
long-term culture, unlimited
source of cells, high-throughput drug screening
and personalised medicine (gene therapy)
PSCs express foetal markers,
limited cell maturation/cell function,
failure to recapitulate
multiple cell types of the liver
Liver-on-a-chip109 In vitro NAFLD/NASH,
ACLD
PHH, IC, NPC Dynamic fluid flow, commercially available,
single and multi-chamber design,
sustained functionality for at least 4 weeks,
modelling zonal liver phenotypes possible
Low throughput drug screening,
access to fresh human tissue, healthy







Whole tissue Reproducible, low cost, hepatic environment and
ECM present, low amount of tissue
Access to fresh tissue, healthy tissue
not really extracted from healthy
individuals, functions as metabolic





PHH, IC, NPC Provides a neutral environment that mimics
(patho)physiological conditions,
low antigenicity, simple and safe protocol
Divergence in decellularisation
and recellularisation protocols,
reendothelisation is a concern,
long-term engraftment
ACLD, advanced chronic liver disease; ALD, alcohol-related liver disease; ASH, alcohol-related steatohepatitis; CCA, cholangiocarcinoma; ECM, extracellular matrix; HCC,
hepatocellular carcinoma; IC, immortalised cell lines; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NPC, non-parenchymal cells; PHH, primary
human hepatocytes; PSCs, pluripotent stem cells.reproducible model for the study of cholestatic
disease. However, it should be noted that an
exaggerated dilatation of the remnant extrahepatic
bile duct could lead to extrinsic compression of
portal vascular structures. Mortality in this model
is moderate and mainly due to the occasional
perforation of a biliary cyst, or the gallbladder in
mice, and subsequent choleperitoneum. This can
be avoided by performing a concomitant chole-
cystectomy in mice. On a similar note, the risk of
biliomas can be significantly decreased by ligating
all extrahepatic bile duct branches. Finally, another
main drawback of this model is that it cannot be
used for the evaluation of drugs that are eliminated
through the biliary route.
Modelling primary liver cancer:
hepatocellular carcinoma and
cholangiocarcinoma
ACLD is a common risk factor for the development of
liver cancer. In the last few years a number of in vivo
models of HCC and cholangiocarcinoma (CCA)— the
main primary liver cancers — have been developed.
The ideal animal model of HCC/CCA must be immu-
nocompetent and/or developed in a host with a
species-matched microenvironment, with a full im-
mune response including all immune cell subsets
and chemokine signalling. Moreover, tumours must
develop relatively quickly and recapitulate the ge-
netic (e.g. driver mutations), anatomic, and pheno-
typic features of human HCC/CCA.
A variety of strategies have been used to
generate primary liver cancer in rodents. These
include genetic modifications such as expression of
oncogenes (e.g. MYC, Kras/PTEN),31,98–102 disrup-
tion of single or multiple tumour suppressor genesJourna(e.g. NEMO, TAK),103,104 or stem cell trans-
duction.105 Comorbid liver disease can be modelled
by the injection of chemotoxic agents.98–102 Xeno-
graft models are based on the implantation of
tumour cells in hosts that lack a fully functional
immune system.100,101,106 The future success of
these models will depend on the establishment of
immunocompetent humanised mice (e.g. pre-
transplantation with human hematopoietic
cells).107
Future perspectives
Although animal models are still the best approach
to comprehensively study the pathophysiology of
liver diseases and to develop new drugs, some-
times translating the findings from animals to
humans can be challenging. Thus, complementary
advanced in vitro 3D human cellular culture sys-
tems have been developed to enable researchers to
study specific cellular functions and regulation, as
well as drug efficacy and toxicity, in a liver-centred
environment. Spheroids consisting of primary hu-
man hepatocytes or immortalised cell lines and
pluripotent stem cell-derived organoids have
benefited from the understanding of ECM biology.
Both bioengineering systems have been applied to
the understanding of NAFLD/NASH, whilst the
expansion and establishment of organoids as
tumouroids for the study of primary liver cancer
has great potential, but has not yet been explored
for precision oncology.108 When the goal is to
better recapitulate the microphysiological condi-
tions occurring at the hepatic sinusoid, the liver-
on-a-chip system adds the biophysical factors,
such as shear stress and hydrodynamic pressure
that normally affect liver sinusoidal endotheliall of Hepatology 2020 vol. - j 1–18 13
Author names in bold design
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Reviewcells, and paracrinally affect other cells. These
advanced in vitro systems may use immortalised
liver cells, and importantly primary cells isolated
from human livers.109,110 Additionally, precision-
cut tissue slices represent an ex vivo tissue cul-
ture technique by which different stages of
(human) liver AFLD/ASH, NAFLD/NASH and HCC
have been successfully investigated.111,112 Last but
not least, the decellularisation and repopulation of
human liver represents the present and the future
of hepatic tissue bioengineering113,114 (Table 5).
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